Chemical Property of Ripasudil hydrochloride dihydrate
Chemical Property:
- PSA：89.14000
- LogP:3.76730
- Solubility.:insoluble in EtOH; ≥123.2 mg/mL in DMSO; ≥41.7 mg/mL in H2O
- Hydrogen Bond Donor Count:4
- Hydrogen Bond Acceptor Count:8
- Rotatable Bond Count:2
- Exact Mass:395.1081833
- Heavy Atom Count:25
- Complexity:482
- Purity/Quality:
-
99% *data from raw suppliers
RipasudilHydrochloride *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- Statements:
24/25-26-28
- Safety Statements:
28-38-41-48
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CC1CNCCCN1S(=O)(=O)C2=CC=CC3=CN=CC(=C32)F.O.O.Cl
- Isomeric SMILES:C[C@H]1CNCCCN1S(=O)(=O)C2=CC=CC3=CN=CC(=C32)F.O.O.Cl
- Recent ClinicalTrials:A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
- Recent EU Clinical Trials:A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and
- Recent NIPH Clinical Trials:Study on the Safety of Rho-kinase Inhibitor (Ripasudil) with Needling
-
Description
Ripasudil hydrochloride hydrate (Glanatec?) was approved in
Japan in 2014 for the treatment of glaucoma and ocular hypertension.
Originally discovered by D. Western Therapeutics Institute,
Inc. and licensed by the Kowa Company, Ltd, ripasudil
functions as a selective Rho-kinase inhibitor and reduces intraocular
pressure by stimulation of aqueous humour drainage of the
trabecular meshwork. While this recent approval allows
for use of ripasudil as a twice-daily monotherapy treatment when
other drugs cannot be used or are not effective, clinical trials
using ripasudil as a combination therapy with other glaucoma
drugs have shown promising results in the treatment of primary
open-angle glaucoma or ocular hypertension. Currently, the
Kowa Company is also pursuing trials focused on the use of
ripasudil for the treatment of diabetic retinopathy and diabetic
macular edema.
